AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06270498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrosomial iron
Description: Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 12 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-15 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 12 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 12 weeks
Study NCT06270498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be identical in shape, form and color of SI pills; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin D.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm.
Study NCT04885361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVepiT (OSE13E)
Description: Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
Study NCT04733118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and Pertuzumab (FDC SC) and T-DM1
Description: Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1.
Study NCT05447520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
Study NCT05447520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet once daily
Study NCT05447520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional DMARDs
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Study NCT05447520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional DMARDs
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Study NCT06391008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f
Study NCT06391008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evoximab
Description: Evoximab (20mg/kg, Q3W)
Study NCT06391008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500mg/m2, Q3W)
Study NCT06391008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin Paclitaxel 260 mg/m2, Q3W
Study NCT06391008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC5, Q3W)
Study NCT05139719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585 dose A
Description: taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
Study NCT05139719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC585 dose A
Description: taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
Study NCT05139719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585 dose B
Description: taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
Study NCT05139719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taking Placebo orally once daily, up to 24 weeks in main stage
Study NCT05103501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）
Description: immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
Study NCT04473924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Body surface area-based dosing of mycophenolate
Study NCT04473924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Standard (fixed) dosing of mycophenolate
Study NCT05109689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-P
Description: ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
Study NCT05109689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: T4C
Description: T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
Study NCT05637541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG141
Description: The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
Study NCT05637541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GST-HG141
Description: The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
Study NCT05347563 — intervention group
Intervention type: PROCEDURE
Intervention: Electrical impedance tomography
Description: All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment...)
Study NCT05807191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care based on kangaroo care guide
Description: Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
Study NCT05528562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Rapid Access
Description: 'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
Study NCT05528562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Description: After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
Study NCT05528562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried blood spot testing
Description: HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
Study NCT06235229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F
Description: GC012F is a BCMA/CD19 dual CAR product
Study NCT05297292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW02
Description: MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
Study NCT05297292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: a recombinant anti-VEGF humanized monoclonal antibody injection
Study NCT06082323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-002-158/Placebo oral tablet(s)
Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Study NCT04785950 — intervention group
Intervention type: DRUG
Intervention: Low-dose levonorgestrel intrauterine systems (LNG-IUS)
Description: Any low-dose intrauterine system (IUS) marketed in Spain
Study NCT05215470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
Study NCT05215470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
Study NCT06234579 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy (tissue or liquid)
Description: At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA.
Study NCT04884217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pro-ocular™ Topical Gel
Description: Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
Study NCT04884217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
Study NCT05336019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self-management Coaching
Description: A 12-week Diabetes self-management coaching program
Study NCT05336019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
Study NCT05794672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elarekibep
Description: Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
Study NCT06204913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu label
Description: Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
Study NCT05794672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single or multiple inhaled doses A, B or C.
Study NCT06338813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Manometry
Description: The Compass Lumbar Puncture Pressure Transducer (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer. After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted.
Study NCT05402111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
Study NCT05507567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neumifil
Description: Liquid for intranasal spray administration
Study NCT05507567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Liquid for intranasal spray administration
Study NCT05507567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid for intranasal spray administration
Study NCT05849675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant 17.8 MG [Wakix]
Description: Single dose pitoliosant (36mg)
Study NCT05849675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo
Study NCT06510803 — intervention group
Intervention type: DRUG
Intervention: The case intervention is the sevoflurane concentrations with the Drager Apollo workstation
Description: The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
Study NCT06305299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR.B7-H3 T cells
Description: iC9-CAR.B7-H3 T cells will then be administered intraperitoneally
Study NCT06305299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 300 mg/m2 IV will be given.
Study NCT06305299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine 30 mg/m2 IV will be given.
Study NCT06410352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, Empagliflozin
Description: subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
Study NCT06410352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minigastric bypass
Description: Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.
Study NCT06410352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Analimentary detoxication
Description: very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.
Study NCT06410352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ramadan fast's weight loss
Description: The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset).
Study NCT06225518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized physical activity management system
Description: Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
Study NCT05508984 — intervention group
Intervention type: DEVICE
Intervention: Amma Cooling Caps
Description: Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen.
Study NCT05607173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole (HOE239)
Description: Route of administration: oral; pharmaceutical form: tablet
Study NCT05402111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Description: PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
Study NCT05833191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular vagus stimulation
Description: When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
Study NCT05833191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial Nerve Stimulation
Description: When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
Study NCT04661540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620-IE (Injectable Emulsion)
Description: Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
Study NCT04661540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
Study NCT04720820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Supported discharge with home based Rehabilitation
Description: Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
Study NCT04720820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Treatment will be provided according to current hospital's stroke rehabilitation program.
Study NCT06221215 — intervention group
Intervention type: PROCEDURE
Intervention: trauma
Description: The main purpose of this study is to observe whether the early hormone changes and trends in the two groups of patients with or without trauma.
Study NCT06046859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
Study NCT06046859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
Study NCT06213233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
Study NCT06213233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).